Wegovy leadership in obesity remains strong as Lilly doubles down on emerging entry with tirzepatide. While Novo Nordisk continues to have a virtual monopoly on the GLP space for obesity, posting huge growth in uptake and sales of Wegovy, Lilly is close on their heels.